The Off-Label Revolution Driven by Genomic Profiling: A New Horizon in Precision Oncology
-
The Power of Precision Medicine Demonstrated by 20,000 Genomes This unprecedentedly large clinical trial, involving 30 institutions worldwide, shattered conventional notions of cancer therapy. Instead of using standard treatments approved for specific cancer types, the research team focused on the individual tumor's "genomic profile." They adopted a genomics-guided strategy to match drugs precisely to mutated genes, irrespective of tumor location (lung, liver, breast, etc.).
-
Off-Label Matching: Genetic Targeting Beyond Approved Indications A central element of this study was the proactive use of off‑label (i.e., non‑indicated) prescriptions. For instance, even a drug approved for breast cancer was matched to a gastric cancer patient when the patient’s tumor harbored a mutation susceptible to that drug.
- Enhanced progression inhibition: The proportion of patients whose disease progression slowed markedly increased by 35% compared with the standard‑treatment arm.
- Achievement of complete remission: In certain cohorts, complete disappearance of cancer cells (Complete Remission) was observed, demonstrating the potent efficacy of the off‑label approach.
- A New Lifeline for Patients with Rare Mutations The approach proved especially illuminating for patients harboring rare genetic alterations for which therapeutic options are scarce.
- Survival improvement >20%: In the rare‑mutation cohort, personalized off‑label therapy increased survival by more than 20% relative to conventional treatment.
- Breakthrough for rare cancers: The data demonstrate that, even in the absence of extensive clinical evidence, genomic information alone can confer tangible therapeutic benefit to patients with orphan cancers.
- Outlook: Building an Integrated Genomic Treatment Platform Building on these results, the investigators aim to develop a comprehensive, personalized treatment platform that integrates expanded drug databases with genomic data. Cancer therapy is now transitioning from asking “where is the tumor located?” to asking “which genetic alteration drives the tumor?”
Nature, Published online: 15 April 2026; doi:10.1038/d41586-026-01241-0Genomics-guided trial could increase options for people undergoing cancer therapy — plus, a landmark ancient-genome study reveals natural selection in hundreds of human genes.
This study demonstrates that unapproved drugs can be effectively repurposed using only genomic information. Societally, this approach can expand treatment access and reduce drug development costs, delivering substantial benefits to patients and healthcare systems alike.